<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03281278</url>
  </required_header>
  <id_info>
    <org_study_id>003</org_study_id>
    <nct_id>NCT03281278</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Application of Platelet Mapping in HBV-related Acute-on-chronic-liver Failure in China</brief_title>
  <official_title>A Prospective Study of Application of Platelet Mapping in HBV-related Acute-on-chronic-liver Failure in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease&#xD;
      (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin&#xD;
      production and provides a global assessment of coagulation incorporating the cumulative&#xD;
      effect of the interactions at various levels between plasma components and cellular component&#xD;
      of coagulation. And through the platelet mapping, it can help provide a picture of patients'&#xD;
      function of platelet. This study aims to explore the predictive role of platelet mapping in&#xD;
      ACLF prognosis, organ failure developments and short term mortality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Actual">August 13, 2018</completion_date>
  <primary_completion_date type="Actual">August 13, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28-day</time_frame>
    <description>death within 28-day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day progression</measure>
    <time_frame>28-day</time_frame>
    <description>progressed to EASL defined ACLF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90-day</time_frame>
    <description>death within 90-day</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Thrombelastography,Acute on Chronic Liver Failure, Platelet</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard treatment</intervention_name>
    <description>standard medical treatment</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HBV-related chronic liver disease, International Normalized Ratio (INR)≥1.5&#xD;
        and total bilirubin≥85μmol/L&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with previously diagnosed or undiagnosed HBV related chronic liver&#xD;
             disease/cirrhosis&#xD;
&#xD;
          -  INR≥1.5 and total bilirubin≥85μmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  INR≤1.5 or total bilirubin≤85μmol/L;&#xD;
&#xD;
          -  underlying chronic liver disease was other than chronic HBV infection related;&#xD;
&#xD;
          -  those who had hepatocellular carcinoma or other types of malignancies;&#xD;
&#xD;
          -  obstructive biliary diseases or other disease lead to bilirubin evaluation;&#xD;
&#xD;
          -  those who had acute hemorrhage one week before admission&#xD;
&#xD;
          -  those who received platelet, cryo transfusion or plasmapheresis one week before&#xD;
             admission&#xD;
&#xD;
          -  using steroid or immunosuppressant or antiplatelet or anticoagulant drugs in 4 weeks&#xD;
&#xD;
          -  any kind of decompensation which persisted over a month&#xD;
&#xD;
          -  pregnancy and breastfeeding&#xD;
&#xD;
          -  those who received liver transplantation or kidney transplantation;&#xD;
&#xD;
          -  combine with other disease lead to organ failure including heart failure (NYHA&#xD;
             IV),respiratory failure（PaO2&lt;60mmHg),renal insufficiency(CKD 5) and conscious&#xD;
             disturbance (GCS&lt;8)&#xD;
&#xD;
          -  readmission;&#xD;
&#xD;
          -  death within 24 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombelastography,acute on chronic liver failure, platelet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

